InnoCan PharmaHAM:IP40 59 Net Current Asset Value is €0.99 as of Mar. 2026, which is 100% below its 10-year median of 11.70. GuruFocus rates HAM:IP40 with a GF Score™ of 59/100 and a GF Value™ of €9.23 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,050 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 82.29% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
InnoCan Pharma's net current asset value per share for the quarter that ended in Mar. 2026 was €0.99.
The historical rank and industry rank for InnoCan Pharma's Net Current Asset Value or its related term are showing as below:
HAM:IP40'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.35 Med: 11.7 Max: 61.9
Current: 1.48
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of InnoCan Pharma was 61.90. The lowest was 1.35. And the median was 11.70.
HAM:IP40's Price-to-Net-Current-Asset-Value is ranked better than 82.29% of 1050
companies
in the Consumer Packaged Goods industry
Industry Median: 4.2
vs HAM:IP40: 1.48
InnoCan Pharma (HAM:IP40) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
InnoCan Pharma Net Current Asset Value Related Terms
InnoCan Pharma Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IP40 vs PG, CL, KVUE: Net Current Asset Value Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Price-to-Net-Current-Asset-Value vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €0.99 mean?
InnoCan Pharma (HAM:IP40) has a Net Current Asset Value of €0.99 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on InnoCan Pharma and its competitors. This is 92% below median its historical median of 11.70. Over the past decade, InnoCan Pharma's Net Current Asset Value has ranged from 1.35 to 61.90. According to the industry distribution chart, InnoCan Pharma ranks #186 out of 1050 companies in the Consumer Packaged Goods industry, placing it in the top 17.7%.
Is InnoCan Pharma's Net Current Asset Value too high?
InnoCan Pharma's current Net Current Asset Value of €0.99 is 92% below median its 10-year median of 11.70. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 61.90. Based on the distribution chart, InnoCan Pharma ranks #186 out of 1050 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCan Pharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Net Current Asset Value compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #186 out of 1050 companies for Net Current Asset Value. This places InnoCan Pharma in the top 18% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.20. Historically, InnoCan Pharma's own Net Current Asset Value has ranged from 1.35 to 61.90 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Consumer Packaged Goods company?
The median Net Current Asset Value among Consumer Packaged Goods companies is 4.20, based on 1,050 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Net Current Asset Value is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Net Current Asset Value is €0.99, which is 92% below median its own 10-year median of 11.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.23, compared to a current price of €1.47 — trading 84.1% below its estimated fair value. The current Net Current Asset Value is €0.99, which is 92% below median its 10-year median of 11.70. InnoCan Pharma's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Net Current Asset Value is €0.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.47 is trading 84.1% below its estimated GF Value™ of €9.23.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Net Current Asset Value: €0.99 (92% below median its 10-year median of 11.70)
GF Value™: €9.23 vs. price of €1.47 (84.1% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
59GF Score
Get the complete analysis for HAM:IP40
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
